- Multiple sample types being sourced for a range of applications requiring internal R&D testing
- Ethics Committee approval received to commence a proof-of-concept study at the Royal Melbourne Hospital (RMH) investigating the utility of Sienna’s hTERT IVD test in thyroid samples
- Thyroid cancer has a significant unmet clinical need
Melbourne, Australia, 30 August 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce it has entered a clinical proof-of-concept study agreement with the Royal Melbourne Hospital (RMH), and received ethics approval to investigate the potential use of its hTERT In- Vitro Diagnostic (IVD) test on Fine Needle Aspirate (FNA) samples from the thyroid gland.
For further information please download PDF attached:
Download this document
